Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrice Benner

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|February 6, 2024
Quality Tolerance Limits: A General Guidance for Parameter Selection and Threshold SettingAnnett Keller, Nathalie van Borrendam, Patrice Benner, et al.
Human Vaccines & Immunotherapeutics|November 15, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccineJames T Peterson, Helen L Stacey, John E MacNair, et al.
Human Vaccines & Immunotherapeutics|January 17, 2019
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adultsHelen L Stacey, Jeffrey Rosen, James T Peterson, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|February 6, 2024
Quality Tolerance Limits: A General Guidance for Parameter Selection and Threshold SettingAnnett Keller, Nathalie van Borrendam, Patrice Benner, et al.
Human Vaccines & Immunotherapeutics|November 15, 2018
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccineJames T Peterson, Helen L Stacey, John E MacNair, et al.
Human Vaccines & Immunotherapeutics|January 17, 2019
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adultsHelen L Stacey, Jeffrey Rosen, James T Peterson, et al.
Pageof 1